Development of a method to control endogenous proteins by integrating genome editing and chemogenetic techniques
| Project/Area Number |
18H02086
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 37010:Bio-related chemistry
|
|---|
| Research Institution | Nagoya Institute of Technology |
|---|
Principal Investigator |
Tsukiji Shinya 名古屋工業大学, 工学(系)研究科(研究院), 教授 (40359659)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2020: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥11,050,000 (Direct Cost: ¥8,500,000、Indirect Cost: ¥2,550,000)
|
|---|
| Keywords | 局在性リガンド / ゲノム編集 / 細胞内在性タンパク質 / タンパク質工学 / シグナル制御 / SLIPT / 光制御 |
|---|
| Outline of Final Research Achievements |
The aim of this work was to develop a new general method for controlling endogenous proteins in living cells. To this end, we took an approach to combine a CRISPR/Cas9-based genome editing technique with our previously established SLIPT (self-localizing ligand-induced protein translocation) method. We first developed a novel engineered dihydrofolate reductase, termed iK6-DHFR, as a protein tag that can be recruited specifically to the plasma membrane (PM) in the presence of a previously reported PM-localizing ligand, mDcTMP. We then established a gene-knock-in protocol to generate cell lines in which a genome-encoded protein of interest is fused in-frame to the iK6-DHFR tag and fluorescent protein. Using cRaf as a target protein, we demonstrated the PM-recruitment of the iK6-DHFR-tagged endogenous cRaf by mDcTMP, which led to the activation of the endogenous Raf/ERK pathway.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、細胞内在性タンパク質の局在と活性を化合物でコントロールすることを可能にする汎用的な手法を開発するものである。このような技術は、細胞や疾患のメカニズムの解明のためのツールとして有用であるばかりでなく、再生医療や細胞治療など、細胞機能の人工制御が基盤となるさまざまなバイオメディカル分野への応用が期待される。
|
Report
(4 results)
Research Products
(65 results)
-
-
-
-
-
-
-
-
[Journal Article] Engineering orthogonal, plasma membrane-specific SLIPT systems for multiplexed chemical control of signaling pathways in living single cells2020
Author(s)
Akinobu Nakamura, Choji Oki, Kenya Kato, Satoko Fujinuma, Gembu Maryu, Keiko Kuwata, Tatsuyuki Yoshii, Michiyuki Matsuda, Kazuhiro Aoki, Shinya Tsukiji
-
Journal Title
ACS Chemical Biology
Volume: 15
Issue: 4
Pages: 1004-1015
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
